Key Stats for Cardinal Health Stock
- Current Price: $211
- Target Price: $290
- Target Return: 30.6%
- Annualized IRR: 6.4%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
The prevailing market narrative surrounding Cardinal Health, Inc. (CAH) often fixates on the razor-thin margins of traditional pharmaceutical distribution and the geopolitical risks surrounding global supply chains and commodity inflation.
However, the strategic reality detailed at the Leerink Global Healthcare Conference in March 2026 reveals a company that is rapidly transforming its revenue mix through specialized services and operational mastery.
During the conference, CFO Aaron Alt highlighted that all five of the company’s business units delivered double-digit profit growth in the recent quarter.
This structural strength is anchored by Cardinal’s booming Specialty business, which is on track to eclipse $50 billion in revenue this year.
Rather than just distributing drugs, Cardinal has aggressively expanded its Management Services Organization (MSO) footprint.
By acquiring entities like Specialty Networks, Cardinal provides community physicians with advanced software tools, like PPS Analytics and SoNaR, that read across 42 different Electronic Medical Record (EMR) systems.
This relieves doctors of administrative burdens and locks them into Cardinal’s broader ecosystem across high-value specialties like urology and gastroenterology.
Alt also firmly dismissed concerns regarding recent geopolitical tensions and oil price spikes.
Because 99% of Cardinal’s revenue is generated domestically in the U.S., the company has minimal direct exposure to Middle Eastern shipping disruptions.
Furthermore, any raw material inflation affecting manufacturing inputs would not be realized for seven to eight months, giving the company ample time to adjust its pricing contracts.
See historical and forward estimates for Cardinal Health stock (It’s free!) >>>
Is Cardinal Health Undervalued Today?
The market is currently underpricing Cardinal Health’s ability to extract value from the looming wave of pharmaceutical innovation.
Beyond its core distribution, the company is positioning itself as the undisputed partner of choice for complex medical rollouts.
Nowhere is this more evident than in Cardinal’s Nuclear & Precision Health Solutions (NPHS) business.
The company is currently tracking an innovation pipeline of over 70 distinct radiotherapeutics and diagnostics in development.
Because these specialized therapies require highly regulated, time-sensitive logistics, Cardinal’s established nuclear pharmacy network gives it an impenetrable moat.
Furthermore, the company has proven it can execute flawless M&A integration.
Alt noted that following the acquisition of the Advanced Diabetes Supply Group (ADSG), Cardinal absorbed the new unit’s volume, increasing sales in that channel by roughly 30%, while only utilizing 2% of Cardinal’s massive existing capacity.
Despite lingering market fears surrounding the IRA Medicare drug pricing negotiations, Cardinal’s core distribution margins are structurally safe.
Alt addressed the fee-for-service dynamic directly:
“If someone wants to look at what we do and buying from thousands and selling to… 10,000 on a regular basis and tell us that earning a 1% margin is egregious on our part, I will encourage them to look right back at their own gross margin structure.”
When benchmarked against healthcare distribution peers like McKesson (MCK) and Cencora (COR), Cardinal Health’s valuation looks exceptionally compelling.
See whether Cardinal Health is undervalued vs peers (It’s free!) >>>
TIKR Advanced Model Analysis
The TIKR Advanced Model identifies Cardinal Health as a highly stable cash flow generator. The company successfully leverages its massive distribution scale to fund highly accretive acquisitions in specialty and at-home medical markets.
- Current Price: $211
- Target Price: $290
- Target Return: 30.6%
- Annualized IRR: 6.4%
Build a 4-year Valuation Model for Cardinal Health for yourself (It’s free) >>>
The “Scale” Margin Lever: The mechanical path to the $290 target relies heavily on Cardinal Health’s ability to maintain its massive top-line scale while executing its specialized services playbook. The model’s Mid Case assumes a highly robust 7.8% Revenue CAGR over the 5-year forecast period. This steady expansion is driven by the $50 billion Specialty business, the rapid integration of the ADSG diabetes portfolio, and the imminent commercialization of the 70-plus radiotherapeutics in the nuclear pipeline.
By funneling massive volumes through an incredibly efficient infrastructure, where integrating major acquisitions uses only 2% of spare capacity, and fiercely defending its core distribution economics, Cardinal is forecast to maintain a structurally sound 1.0% Net Income Margin over the forecast period.
While 1% sounds thin in a vacuum, applied against hundreds of billions in pharmaceutical revenue, this combination of massive scale and disciplined profitability easily justifies the modeled 6.4% annualized return, making Cardinal Health a highly compelling, defensive healthcare opportunity.
Conclusion: The market’s knee-jerk reaction to macro commodity inflation and Medicare negotiations completely ignores the structural transformation occurring within Cardinal Health’s core business. By successfully expanding its high-margin MSO footprint, dominating the complex logistics of the nuclear medicine pipeline, and executing flawless M&A integration, Cardinal is future-proofing its cash flow. The fundamental upside to a $290 valuation makes Cardinal Health an exceptionally strong total-return opportunity.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Cardinal Health?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Cardinal Health, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Cardinal Health alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Cardinal Health on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
